J B Chemicals & Pharmaceuticals Ltd updates on ANDA Approval by US FDA

The company has announced that US FDA has approved JB Pharma's Abbreviated New Drug Application (ANDA) for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, the generic version of Sinequan (Pfizer), which is indicated for the treatment of anxiety, depression, and other target symptoms of psychoneurosis.

The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat. Doxepin Hydrochloride Capsules had an estimated annual sales of US $23.90 million in the United States (IQVIA MAT Jun' 2023).

Shares of JB Chemicals & Pharmaceuticals Limited was last trading in BSE at Rs. 2652.45 as compared to the previous close of Rs. 2661.90. The total number of shares traded during the day was 823 in over 284 trades.

The stock hit an intraday high of Rs. 2665.00 and intraday low of 2642.45. The net turnover during the day was Rs. 2183139.00.

Source : Equity Bulls

Keywords

JBChemicalsandPharmaceuticals INE572A01028 ANDA Approval USFDA DoxepinHydrochlorideCapsules